Showing results (1011-1020 of 1,396) with videos related to

Sort By:
Pageof 140
JCO Precision Oncology|April 9, 2024
Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol EMonica F Chen, Zihe Song, Helena A Yu, et al.
JCO Precision Oncology|April 5, 2024
Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRASG12C-Mutated Non-Small Cell Lung Cancer: A Case Series and Literature ReviewJia Luo, Narjust Florez, Anjali Donnelly, et al.
JCO Precision Oncology|April 2, 2024
Solving Missing Heritability in Patients With Familial Adenomatous Polyposis With DNA-RNA Paired TestingColin C Young, Carolyn Horton, Jessica Grzybowski, et al.
JCO Precision Oncology|October 26, 2023
Intronic Germline DICER1 Variants in Patients With Sertoli-Leydig Cell TumorClaudette R Fraire, Paige R Mallinger, Jessica N Hatton, et al.
JCO Precision Oncology|November 9, 2023
Implementation of Precision Oncology in the National Healthcare System: A Statement Proposal Endorsed by Italian Scientific SocietiesGianpiero Fasola, Maria C Barducci, Valeria D Tozzi, et al.
JCO Precision Oncology|April 9, 2026
Bespoke Circulating Tumor DNA Testing for Diagnostic Resolution, Disease Surveillance, and Treatment Monitoring in Hepatopancreatobiliary Malignancies: A Real-World ExperienceOluseyi Abidoye, Angelo Pirozzi, Naohiro Okano, et al.
JCO Precision Oncology|March 30, 2026
Prognostic Biomarkers and Immunotherapeutic Insights of Circulating Tumor DNA Analysis in Advanced Esophageal Squamous Cell Carcinoma From SCRUM-MONSTAR GOZILA SubstudyYuqing Duan, Tadayoshi Hashimoto, Taro Shibuki, et al.
JCO Precision Oncology|April 30, 2026
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry StudyErin F Cobain, Michael Rothe, Elizabeth Garrett-Mayer, et al.
JCO Precision Oncology|April 16, 2026
Genome Sequencing of Undiagnosed European Patients Suspected of Hereditary Cancer: Diagnostic Yield and Identification of Candidate Causative VariantsNelson Martins, Mariona Terradas, José Garcia-Pelaez, et al.
JCO Precision Oncology|June 17, 2026
Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1IShivaani Kummar, Zihe Song, Kim A Reiss, et al.
Pageof 140